Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles

International Journal of Pharmaceutics

Volumn 407, Issue 1-2, 2011, Pages 126-131

  Ito, Yukako ^a   Murano, Hiroshi ^a   Hamasaki, Noriyuki ^a   Fukushima, Keizo ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Degradation in the skin tissue; Dissolving microneedles; Leuprolide acetate; Low bioavailability; Rat

Indexed keywords

CHONDROITIN SULFATE; LEUPRORELIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG HALF LIFE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MICRONEEDLE; NEEDLE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SKIN CULTURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHONDROITIN SULFATES; CHROMATOGRAPHY, LIQUID; HALF-LIFE; INCIDENCE; LEUPROLIDE; MALE; NEEDLES; RATS; RATS, WISTAR; SKIN ABSORPTION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 79952310517     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.01.039     Document Type: Article

References (42)

1. Adjei, A., Sundberg, D., Miller, J., Chun, A., 1992. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. 9, 244-249.
2. Bauer, J., Bahmer, F.A., Wörl, J., Neuhuber, W., Schuler, G., Fartasch, M., 2001. A strikingly constant ration exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical dissector method and the confocal laser scanning microscope. J. Invest. Dermatol. 116, 313-318.
3. Bando, H., Sahashi, M., Takagi, T., Yamashita, F., Takakura, Y., Hashida, M., 1996. Analysis of in vitro skin penetration of acyclovir prodrugs based on a diffusion model with metabolic process. Int. J. Pharm. 135, 91-102.
4. Bando, H., Sahashi, M., Yamashita, F., Takakura, Y., Hashida, M., 1997. In vivo evaluation of acyclovir prodrug penetration and metabolism through rat skin using a diffusion/bioconversion model. Pharm. Res. 14, 56-62.
5. Davis, S.P., Martanto, W., Allen, G.M., Prausnitz, M.R., 2005. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE. Trans. Biomed. Eng. 52, 909-915.
6. Degim, T.I., Celebi, N., 2007. Controlled delivery of peptides and proteins. Curr. Pharm. Des. 13, 99-117.
7. De Jager, M.W., Ponec, M., Bouwstra, J.A., 2007. The lipid organization in stratum corneum and model systems based on ceramides. In: Enhancement in Drug Delivery. CRC, London, pp. 217-232.
8. Faissner, A., Clement, A., Lochter, A., Streit, A., Mandl, C., Schachner, M., 1994. Isolation of a neural chondmitin sulfate proteoglycan with neurite outgrowth promoting properties. J. Cell. Biol. 126, 783-799.
9. Fukushima, K., Ise, A., Morita, H., Hasegawa, R., Ito, Y., Sugioka, N., Takada, K., 2011. Two-layered dissolving microneedles for percutaneous delivery of peptide/ protein drugs in rats. Pharm. Res. 28, 7-21.
10. Fukushima, K., Yamazaki, T., Hasegawa, R., Ito, Y., Sugioka, N., Takada, K., 2010. Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. Diabetes Technol. Ther. 12, 465-474.
11. Fujino, M., Fukuda, T., Shinagawa, S., Kobayashi, S., Yamazaki, I., 1974. Synthesic analogs of luteinizing hormone-releasing hormone (LH-RH) substituted in position 6 and 10. Biochem. Biophys. Res. Commun. 60, 406-413.
12. Guo, J., Ping, Q., Jing, G., Hung, L., Tong, Y., 2003. Chitosan-coated liposomes: characterization and interaction with leuprolide. Int. J. Pharm. 260, 167-173.
13. Hall, S.C., Tan, M.M., Leonard, J.J., Stevenson, C.L., 1999. Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide. J. Pept. Res. 53, 432-441.
14. Hayashi, T., Iida, Y., Hatanaka, T., Kawaguchi, T., Sugibayashi, K., Morimoto, Y., 1997. The effects of several penetration enhancers on the simultaneous transport and metabolism of ethyl nicotinate in hairless rat skin. Int. J. Pharm. 154, 141-148.
15. Henry, S., McAllister, D.V., Allen, M.G., Prausnitz, M.R., 1998. Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci. 87, 922-925.
16. Ito, Y., Hagiwara, E., Saeki, A., Sugioka, N., Takada, K., 2006a. Feasibility of microneedles for percutaneous absorption of insulin. Eur. J. Pharm. Sci. 29, 82-88.
17. Ito, Y., Yoshimitsu, J., Shiroyama, K., Sugioka, N., Takada, K., 2006b. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J. Drug Target 14, 255-262.
18. Ito, Y., Shiroyama, K., Yoshimitsu, J., Ohashi, Y., Sugioka, N., Takada, K., 2007. Pharmacokinetic and pharmacodynamic studies following percutaneous absorption of erythropoietin micropiles to rats. J. Control. Rel. 121, 176-180.
19. Ito, Y., Ohashi, Y., Saeki, A., Sugioka, N., Takada, K., 2008a. Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. Chem. Pharm. Bull. 56, 243-246.
20. Ito, Y., Saeki, A., Shiroyama, K., Sugioka, N., Takada, K., 2008b. Percutaneous absorption of interferon-alpha by self-dissolving micropiles. J. Drug Target 16, 243-249. (Pubitemid 351460653)
21. Ito, Y., Ohashi, Y., Shiroyama, K., Sugioka, N., Takada, K., 2008c. Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. Biol. Pharm. Bull. 31, 1631-1633.
22. Ito, Y., Yamazaki, T., Sugioka, N., Takada, K., 2009. Self-dissolving micropile array tips for percutaneous administration of insulin. J. Mater. Sci-Mater. Med. 21, 835-841.
23. Laimou, D.K., Katsara, M.,Matsoukas, M.T., Apostolopoulos, V., Troganis, A.N., Tselios, V.T., 2010. Structural elucidation of leuprolide and its analogues in solution: insight into their bioactive conformation. Amino acids 39, 1147-1160.
24. McAllister, D.V., Wang, P.M., Davis, S.P., Park, J.H., Canatella, P.J., Allen, M.G., Prausnitz, M.R., Kaushik, S., 2003. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. U.S.A. 100, 13755-13760.
25. Monteiro-Riviere, N.A., Bristol, D.G., Manning, T.O., Rogers, R.A., Riviere, J.E., 1990. Interspecies and interregional analysis of the comparative histologic thickness and laser Doppler blood flow measurements at five cutaneous sites in nine species. J. Invest. Dermatol. 95, 582-586.
26. Morawski, M., Alpár, A., Brückner, G., Fiedler, A., Jäger, C., Gati, G., Stieler, J.T., Arendt, T., 2009. Chondroitin sulfate proteoglycan-based extracellular matrix in chicken (Gallus domesticus) brain. Brain. Res. 1275, 10-23.
27. Nanda, A., Chen, M.H., Moran, B.J., Braccioforte, M.H., Dosoretz, D., Salenius, S., Katin, M., Ross, R., D'Amico, A.V., 2009. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biolo. Phys. 76, 1439-1444.
28. Okada, H., Yamazaki, I., Yashiki, T., Shimamoto, T., Mima, H., 1984. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats IV: evaluation of the vaginal absorpton and gonadotropin responses by radioimmunoassay. J. Pharm. Sci. 73, 298-302.
29. Park, J.H., Allen, M.G., Prausnitz, M.R., 2006. Polymer microneedles for controlledrelease drug delivery. Pharm. Res. 23, 1008-1019.
30. Sennello, L.T., Finley, R.A., Chu, S.Y., Jagst, C., Max, D., Rollins, D.E., Tolman, K.G., 1986. Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J. Pharm. Sci. 75, 158-160.
31. Singh, S., Singh, J., 2007. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int. J. Pharm. 328, 42-48.
32. Sintov, A., Di-Capua, N., Rubinstein, A., 1995. Cross-linked chondroitin sulfate: characterization for drug delivery purposes. Biomaterials 16, 473-478.
33. Sofianos, Z.D., Katsila, T., Kostomitsopoulos, N., Balafas, V., Matsoukas, J., Tselios, T., Tamvakopoulos, C., 2008. Tamvakopoulos: in vivo and in vitro metabolism of leuprolide in mice-mass spectrometry-based biomarker measurement for efficacy and toxicity. J. Mass. Spectrom. 43, 1381-1392.
34. Takada, K., 2008. Microfabrication derived DDS: from batch to individual production. Drug. Discov. Ther. 2, 140-155.
35. Teo, M.A.L., Shearwood, C., Ng, K.C., Lu, J., Moochhala, S., 2005. In vitro and in vivo characterization of MEMS microneedles. Biomed. Microdevices 7, 47-52.
36. Toguchi, H., Ogawa, Y., Okada, H., Yamamoto, M., 1991. Once-a-month injectable microspheres of leuprorelin acetate. Yakugaku Zasshi 111, 397-409.
37. Tombal, B., Miller, K., Gibod, L., Schröder, F., Shore, N., Crawford, E.D., Moul, J., Jensen, J., Olesen, T.K., Persson, B., 2010. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 57, 836-842.
38. Tsai, M.F., Chiang, Y.L., Wang, L.F., Huang, G.W., Wu, P.C., 2005. Oral sustained delivery of diclofenac sodium using calcium chondroitin sulfate matrix. J. Biomater. Sci. Polym. Ed. 16, 1319-1331.
39. Umehara, Y., Yamada, S., Nishimura, S., Shioi, J., Robakis, N.K., Sugahara, K., 2004. Chondroitin sulfate of appican, the proteoglycan form of amyloid precursor protein, produced by C6 glioma cells interacts with heparin-binding neuroregulatory factors. FEBS. Lett. 557, 233-238.
40. Wilson, M.T., Snow, D.M., 2000. Chondroitin sulfate proteoglycan expression pattern in hippocampal development: potential regulation of axon tract formation. J. Comp. Neurol. 424, 532-546.
41. Woo, B.H., Kostanski, J.W., Gebrekidan, S., Dani, B.A., Thanoo, B.C., Deluca, P.P., 2001. Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres. J. Cont. Rel. 75, 307-315.
42. Yoshikawa, Y., Kato, K., Sone, H., Takada, K., 1998. Development and evaluation of noncompartmental pharmacokinetic analysis program "WinHARMONY" using Visual BASIC language having a function of an automatic recognition of terminal elimination phase of plasma drug concentration vs. time profile. Jpn. J. Clin. Pharmacol. Ther. 29, 475-487.